Holen Sie sich die Stockscreener-App
19.56
0.61%
-0.12
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics Executives Sell Shares to Cover Tax Liabilities - TradingView
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK) - Eastern Progress
Stoke Therapeutics stock hits 52-week high at $18.61 - Investing.com India
Stoke Therapeutics stock hits 52-week high at $18.61 By Investing.com - Investing.com Canada
Stoke Therapeutics shares rise 1.27% intraday after announcing inducement grants to new employees. - AInvest
Stoke Therapeutics shares fall 3.24% premarket after Purcell & Lefkowitz LLP announces shareholder investigation. - AInvest
Stoke Therapeutics' Strategic Stock Grants: Fueling Leadership Stability and Long-Term Value Creation in Biotech - AInvest
Stoke Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | STOK Stock News - GuruFocus
Stoke Therapeutics Inc. Approaches Psychological Resistance LevelWeekly Volume Report & Weekly Sector Rotation Insights - classian.co.kr
BTIG Maintains Buy Rating on Stoke Therapeutics with $28 Price Target - AInvest
Purcell & Lefkowitz LLP Investigates Stoke Therapeutics on Shareholder Breach of Fiduciary Duties - AInvest
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK) - MarketScreener
Stoke Therapeutics price target lowered to $28 from $29 at BTIG - TipRanks
Stoke Therapeutics stock price target lowered to $28 at BTIG on Zorevunersen data - Investing.com
Watch for Trend Continuation in Stoke Therapeutics Inc. Next WeekQuarterly Trade Report & Free Expert Approved Momentum Trade Ideas - beatles.ru
Building trade automation scripts for Stoke Therapeutics Inc.Market Volume Summary & Safe Capital Growth Tips - Newser
Multi asset correlation models including Stoke Therapeutics Inc.July 2025 Selloffs & Real-Time Volume Analysis - Newser
Cantor Fitzgerald Has Positive View of STOK FY2025 Earnings - Defense World
Ranking Stoke Therapeutics Inc. among high performing stocks via toolsRisk Management & Free Expert Verified Stock Movement Alerts - Newser
Stoke Therapeutics Receives Buy Rating from Leerink Partners with $18 Price Target - AInvest
HC Wainwright Analysts Lift Earnings Estimates for STOK - Defense World
Wedbush Equities Analysts Raise Earnings Estimates for STOK - Defense World
Is Stoke Therapeutics Inc. stock ready for a breakoutMarket Sentiment Report & Low Risk Profit Maximizing Plans - Newser
What MACD and RSI say about Stoke Therapeutics Inc.July 2025 Analyst Calls & Expert Approved Momentum Ideas - Newser
Biogen Shares Surge 2.71% on $230M Volume Boosted by Pipeline Progress Ranks 444th in Market Activity - AInvest
Allan, general counsel, sells $205k in Stoke Therapeutics (STOK) By Investing.com - Investing.com Nigeria
Allan, general counsel, sells $205k in Stoke Therapeutics (STOK) - Investing.com
Stoke Therapeutics (NASDAQ:STOK) Shareholders Are up 30% This Past Week, but Still in the Red Over the Last Five Years - 富途牛牛
How Stoke Therapeutics Inc. stock performs during market volatility2025 Growth vs Value & Consistent Return Investment Signals - thegnnews.com
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate - simplywall.st
Stoke Therapeutics Inc. May Be Forming Higher Low — Chartwatchers Alert2025 Key Highlights & Capital Efficiency Focused Ideas - beatles.ru
Wedbush Forecasts Strong Price Appreciation for Stoke Therapeutics (NASDAQ:STOK) Stock - Defense World
Stoke Therapeutics Inc. Stock Poised for Technical ComebackMarket Activity Recap & Daily Stock Momentum Reports - newsimpact.co.kr
Stocks With Rising Relative Price Strength: Stoke Therapeutics - MSN
Healthcare Stocks Under Analyst Spotlight: Lyra Therapeutics, Stoke Therapeutics, and Astria Therapeutics. - AInvest
Stoke Therapeutics Impresses With Strong Results For Dravet Syndrome Drug - Finimize
Stoke Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Given Buy Rating at Chardan Capital - Defense World
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up on Strong Earnings - Defense World
Stoke Therapeutics (NASDAQ:STOK) Sets New 12-Month High on Analyst Upgrade - Defense World
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates - MSN
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Stoke Therapeutics Skyrockets 25.57%—What’s Fueling This Biotech Surge? - AInvest
Stoke Therapeutics Reports 'Impressive' Data for Severe Epilepsy Treatment, Wedbush Says - MarketScreener
Stoke Therapeutics Launches Global Phase III Trial of Zorevunersen for Dravet Syndrome. - PharmiWeb.com
Stoke Therapeutics shares rise 3.10% premarket after dosing first patient in Phase 3 trial of Zorevunersen for Dravet Syndrome. - AInvest
Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Promising Developments in Stoke Therapeutics’ Clinical Trials Support Buy Rating - TipRanks
Stoke Therapeutics: Promising Outlook with Strong Financial Position and Advancing Clinical Trials Justifies Buy Rating - TipRanks
Stoke Therapeutics 2025 Q2 Earnings Net Income Cuts Loss by 8.6% - AInvest
Stoke Therapeutics Q2 Loss Narrows, Revenue Rises - 富途牛牛
Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ... - Yahoo Finance
Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ... By GuruFocus - Investing.com Canada
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - BioSpace
Earnings call transcript: Stoke Therapeutics beats Q2 2025 expectations - Investing.com
Stoke Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Stoke Therapeutics shares rise 2.73% after-hours following positive Q2 results and Phase 3 trial initiation. - AInvest
Stoke Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Stoke Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
STOKE THERAPEUTICS Earnings Results: $STOK Reports Quarterly Earnings - Quiver Quantitative
Stoke Therapeutics Q2 2025 slides: Phase 3 Dravet trial underway, ADOA program advances - Investing.com Canada
0.94%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):